Erlotinib Hydrochloride

CAS 183319-69-9 16 current records 10 historicalSmall Molecule

Who holds supplier records for Erlotinib Hydrochloride? 16 organisations hold a current record for Erlotinib Hydrochloride: an active US FDA Type II Drug Master File or a CEP. A further 10 organisations have only historical (inactive) DMF filings. 2 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (10), China (2), Canada (1), United States (1) and 1 other country (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Erlotinib Hydrochloride: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/erlotinib-hydrochloride

Reading the evidence

  • 16 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    10 of the 15 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 9 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (16)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Erlotinib Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Erlotinib Hydrochloride sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (2)

Certificates of Suitability on the EDQM register for Erlotinib Hydrochloride, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 4 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
HETERO LABS LIMITED HyderabadIN
CEP 2024-455 - Rev 01
Erlotinib hydrochloride, Form-A
Sept 2026—
MSN LABORATORIES PRIVATE LIMITED SangareddyIN
CEP 2026-008 - Rev 00
Erlotinib hydrochloride, Crystalline Form-B, Micronised and Non-micronised
Jun 2026Inspected Aug 2026
Slovakia

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (10)

Organisations whose Type II DMFs for Erlotinib Hydrochloride are no longer active. These show a past filing, not current supply.

Show all 10 historical records

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Erlotinib Hydrochloride is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1079742).

Chemical identity

IUPAC name
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride
Canonical SMILES
COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl
InChIKey
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Synonyms
CP-358, CP-358,774-01, CP-358774-01, Erlotinib hcl, Erlotinib hydrochloride, OSI-774, Tarceva, OSI 774, CP 358774, CP-358774, NSC 718781, NSC718781

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor
Mechanism of action
Protein Kinase Inhibitors

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Erlotinib Hydrochloride?

16 organisations hold an active US FDA Type II Drug Master File or a CEP for Erlotinib Hydrochloride: MSN Laboratories Private Limited (India), CDYMAX (INDIA) PHARMA PRIVATE LIMITED (India), Hetero Labs Limited (India), Alembic Pharmaceuticals Limited (India), Apotex Inc. (Canada), CAMBREX CHARLES CITY INC (United States), Cipla Limited (India) and HIKMA PHARMACEUTICALS LLC, and 8 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Erlotinib Hydrochloride Drug Master Files are active?

MSN Laboratories Private Limited (DMF 32324, 27042), CDYMAX (INDIA) PHARMA PRIVATE LIMITED (DMF 36007, 33226), Hetero Labs Limited (DMF 26116), Alembic Pharmaceuticals Limited (DMF 30392), Apotex Inc. (DMF 26631), CAMBREX CHARLES CITY INC (DMF 29809), Cipla Limited (DMF 29638) and HIKMA PHARMACEUTICALS LLC (DMF 29437) and 8 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Erlotinib Hydrochloride records mean?

10 organisations have only inactive Type II DMFs for Erlotinib Hydrochloride. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Erlotinib Hydrochloride have a European Certificate of Suitability?

Yes. 2 organisations hold a valid CEP for Erlotinib Hydrochloride on the EDQM register, including HETERO LABS LIMITED Hyderabad (IN) and MSN LABORATORIES PRIVATE LIMITED Sangareddy (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Erlotinib Hydrochloride supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Erlotinib Hydrochloride?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.